Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

This study is currently recruiting participants.

Verified by National Cancer Institute (NCI), July 2009

First Received: May 9, 2009 Last Updated: July 7, 2009 History of Changes

Sponsored by:	University of California, Davis
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00899405

Purpose

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.

Condition	Intervention
Lung Cancer	Genetic: DNA analysis Genetic: mutation analysis Genetic: polymerase chain reaction

Study Type:	Observational
Official Title:	EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Mutational status of the EGFR pathway [ Designated as safety issue: No ]

Estimated Enrollment:	200
Study Start Date:	May 2005
Estimated Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.
Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.

OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed lung cancer

PATIENT CHARACTERISTICS:

Not specified

PRIOR CONCURRENT THERAPY:

May have received prior EGFR inhibitors

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00899405

Locations

United States, California
University of California Davis Cancer Center	Recruiting
Sacramento, California, United States, 95817
Contact: Clinical Trials Office - University of California Davis Cancer 916-734-3089

Sponsors and Collaborators

University of California, Davis

Investigators

Principal Investigator:

Philip C. Mack, PhD

University of California, Davis

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	CDR0000583056, UCD-155, UCD-200412410
Study First Received:	May 9, 2009
Last Updated:	July 7, 2009
ClinicalTrials.gov Identifier:	NCT00899405 History of Changes
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

lung cancer

Study placed in the following topic categories:

Thoracic Neoplasms
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases

Additional relevant MeSH terms:

Thoracic Neoplasms
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site

Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases

ClinicalTrials.gov processed this record on September 11, 2009